PMID- 30506559
OWN - NLM
STAT- MEDLINE
DCOM- 20190508
LR  - 20190508
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 139
IP  - 4
DP  - 2019 Apr
TI  - BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam 
      in clinical practice.
PG  - 360-368
LID - 10.1111/ane.13059 [doi]
AB  - OBJECTIVES: Evaluate long-term effectiveness and tolerability of brivaracetam in 
      clinical practice in patients with focal epilepsy. MATERIALS AND METHODS: This 
      was a multicenter retrospective study. Patients aged >/=16 years were started on 
      brivaracetam from November 2016 to June 2017 and followed over 1 year. Data were 
      obtained from medical records at 3, 6 and 12 months after treatment initiation 
      for evaluation of safety- and seizure-related outcomes. RESULTS: A total of 575 
      patients were included in analyses; most had been treated with >/=4 lifetime 
      antiepileptic drugs. Target dosage was achieved by 30.6% of patients on the first 
      day. Analysis of primary variables at 12 months revealed that mean reduction in 
      seizure frequency was 36.0%, 39.7% of patients were >/=50% responders and 17.5% 
      were seizure-free. Seizure-freedom was achieved by 37.5% of patients aged 
      >/=65 years. Incidence of adverse events (AEs) and psychiatric AEs (PAEs) was 39.8% 
      and 14.3%, respectively, and discontinuation due to these was 8.9% and 3.7%, 
      respectively. Somnolence, irritability, and dizziness were the most frequently 
      reported AEs. At baseline, 228 (39.7%) patients were being treated with 
      levetiracetam; most switched to brivaracetam (dose ratio 1:10-15). Among those 
      who switched because of PAEs (n = 53), 9 (17%) reported PAEs on brivaracetam, and 
      3 (5.7%) discontinued because of PAEs. Tolerability was not highly affected among 
      patients with learning disability or psychiatric comorbidity. CONCLUSIONS: In a 
      large population of patients with predominantly drug-resistant epilepsy, 
      brivaracetam was effective and well-tolerated; no unexpected AEs occurred over 
      1 year, and the incidence of PAEs was lower compared with levetiracetam.
CI  - (c) 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Villanueva, Vicente
AU  - Villanueva V
AUID- ORCID: 0000-0003-2080-8042
AD  - La Fe University Hospital and Polytechnic, Valencia, Spain.
FAU - Lopez-Gonzalez, Francisco Javier
AU  - Lopez-Gonzalez FJ
AD  - Clinical University Hospital, Santiago, Spain.
FAU - Mauri, Jose Angel
AU  - Mauri JA
AD  - Lozano Blesa University Hospital, Zaragoza, Spain.
FAU - Rodriguez-Uranga, Juan
AU  - Rodriguez-Uranga J
AD  - Advanced Neurological Centre, Sevilla, Spain.
FAU - Olive-Gadea, Marta
AU  - Olive-Gadea M
AD  - Vall d'Hebron University Hospital, Barcelona, Spain.
FAU - Montoya, Javier
AU  - Montoya J
AD  - Lluis Alcanyis Hospital, Xativa, Spain.
FAU - Ruiz-Gimenez, Jesus
AU  - Ruiz-Gimenez J
AD  - Virgen de las Nieves University Hospital, Granada, Spain.
FAU - Zurita, Jorge
AU  - Zurita J
AD  - Infanta Leonor Hospital, Madrid, Spain.
CN  - BRIVA-LIFE study group
LA  - eng
GR  - University of Francisco de Vitoria , Madrid, Spain/
PT  - Journal Article
PT  - Multicenter Study
DEP - 20181227
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Anticonvulsants)
RN  - 0 (Pyrrolidinones)
RN  - U863JGG2IA (brivaracetam)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticonvulsants/*therapeutic use
MH  - Drug Resistant Epilepsy/drug therapy
MH  - Epilepsies, Partial/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pyrrolidinones/*therapeutic use
MH  - Retrospective Studies
MH  - Seizures/prevention & control
MH  - Treatment Outcome
MH  - Young Adult
FIR - Abril, J
IR  - Abril J
FIR - Toledo, M
IR  - Toledo M
FIR - Garces, M
IR  - Garces M
FIR - Gomez-Ibanez, A
IR  - Gomez-Ibanez A
FIR - Hampel, K
IR  - Hampel K
FIR - Rodriguez-Osorio, X
IR  - Rodriguez-Osorio X
FIR - Poza, J J
IR  - Poza JJ
FIR - Campos, D
IR  - Campos D
FIR - Ojeda, J
IR  - Ojeda J
FIR - Tortosa, D
IR  - Tortosa D
FIR - Castro-Vilanova, M D
IR  - Castro-Vilanova MD
FIR - Saiz-Diaz, R
IR  - Saiz-Diaz R
FIR - Gonzalez de la Aleja, J
IR  - Gonzalez de la Aleja J
FIR - Castillo, A
IR  - Castillo A
FIR - de Toledo, M
IR  - de Toledo M
FIR - Gago-Veiga, A B
IR  - Gago-Veiga AB
FIR - Piera, A
IR  - Piera A
FIR - Crisostomo, J
IR  - Crisostomo J
EDAT- 2018/12/07 06:00
MHDA- 2019/05/09 06:00
CRDT- 2018/12/04 06:00
PHST- 2018/10/10 00:00 [received]
PHST- 2018/11/19 00:00 [revised]
PHST- 2018/11/26 00:00 [accepted]
PHST- 2018/12/07 06:00 [pubmed]
PHST- 2019/05/09 06:00 [medline]
PHST- 2018/12/04 06:00 [entrez]
AID - 10.1111/ane.13059 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2019 Apr;139(4):360-368. doi: 10.1111/ane.13059. Epub 2018 Dec 
      27.